Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Multi-Factor Investor model based on the published ...

While the market overall fell by 1.4%, BMY's modest gain suggests that its recent product developments may have provided a counterbalance to the prevailing market trends. Every company has risks ...

There's been a major selloff in Bloomsbury Publishing Plc (LON:BMY) shares in the week since it released its full-year report, with the stock down 21% to UK£4.96. It was a credible result overall ...

There's been a major selloff in Bloomsbury Publishing Plc (LON:BMY) shares in the week since it released its full-year report, with the stock down 21% to UK£4.96. It was a credible result overall, ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

While the market overall fell by 1.4%, BMY's modest gain suggests that its recent product developments may have provided a counterbalance to the prevailing market trends. Every company has risks, and ...

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

**NM signifies a non meaningful value. A dash signifies the data is not available.